Citations 1
Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator
Vella, Adrian , Freeman, Jennifer L. R., Dunn, Imogene, Keller, Kit A., Buse, John B. , Valcarce, Carmen, Vella, Adrian , Keller, Kit, Buse, John B
Science Translational Medicine | January 17, 2019 | Volume: 11 | Issue: 475 | Pages: No page available
A hepatoselective glucokinase activator reduced hyperglycemia without hypoglycemia or adverse effects on lipids, liver enzymes, or blood pressure.